Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPYC Therapeutics Ltd

PYC Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.88 AUD -0.05 ( 2.59%)
Last update at 2026-11-06T05:10:00Z
VOLUME
2333389
Market Cap
1900.57M

Momentum Score

…

PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.79
Low
1.93
High
52 Week Price Range
1.04
Low
2.93
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

PYC Therapeutics Ltd is an Australia-based biotechnology company developing peptide-linked nucleic acid therapeutics for rare genetic diseases and reports a pipeline that includes preclinical and clinical-stage programs. Long-term growth drivers include clinical and regulatory progress, validation of its delivery technology, and partnerships or licensing that could support commercialization, which may appeal to investors seeking exposure to oligonucleotide delivery platforms.

Key risks include clinical and regulatory setbacks, constrained capital and potential dilution, execution and partnership risk, and competition from larger oligonucleotide developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.93
Dividend Yield
-
Revenue TTM
25.99M
Revenue Per Share
0.04
Gross Profit TTM
25.99M
Debt / Equity
0.00
ROE
-10.14%
Net Debt
-52.94M
ROCE
-11.91%
Diluted EPS TTM
-0.06

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -69.76M -51.01M -55.67M -23.36M -14.29M
Minority interest 0.43M 0.71M 0.39M 0.57M 0.43M
Net income -43.34M -50.30M -37.73M -22.79M -14.33M
Selling general administrative 6.69M 7.07M 4.51M 2.54M 4.38M
Gross profit -1.20M 23.49M 22.06M 15.81M -
Reconciled depreciation 0.60M 0.60M 0.60M 0.55M 0.84M
Ebit -82.67M -53.63M -55.62M -23.33M -14.26M
Ebitda -81.47M -52.88M -54.55M -22.78M -13.42M
Depreciation and amortization 1.20M 0.75M 1.07M 0.55M 0.84M
Operating income -82.67M -53.63M -38.86M -23.43M -14.26M
Other operating expenses 82.67M 77.12M 60.92M 39.22M 30.21M
Interest expense 0.04M 0.06M 0.05M 0.03M 0.03M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 13.68M 2.68M 0.80M 0.08M 0.02M
Net interest income 13.64M 2.61M 0.75M 0.05M -0.01M
Income tax expense -25.99M -23.49M -17.56M -0.57M 0.03M
Total revenue - 23.49M 22.06M 15.81M 16.07M
Total operating expenses 81.47M 77.12M 60.92M 39.16M 30.21M
Cost of revenue 1.20M - 1.07M - -
Total other income expense net 12.91M 2.61M -16.81M 15.75M -0.03M
Net income from continuing ops -43.77M -51.01M -38.11M -23.36M -14.29M
Net income applicable to common shares - -50.30M -37.73M -22.79M -13.86M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 708.52M 183.28M 91.24M 37.17M 45.35M
Intangible assets 3.65M 3.85M - 4.25M 4.45M
Other current assets 0.55M 0.41M 0.74M 0.05M 0.07M
Total liab 15.18M 13.27M 10.18M 8.72M 5.15M
Total stockholder equity 693.33M 169.57M 80.50M 27.75M 39.35M
Other current liab 4.16M - 1.27M 3.49M 1.81M
Common stock 933.25M - 230.58M 140.09M 125.99M
Capital stock 933.25M 369.59M - 140.09M 125.99M
Retained earnings -249.54M -206.20M -155.89M -118.17M -95.38M
Other liab - - - 0.18M 0.08M
Other assets - - - 0.00M 0.02M
Cash 53.56M 153.05M 66.87M 15.57M 29.11M
Cash and equivalents - - - 15.57M 29.11M
Total current liabilities 14.40M 12.32M 9.11M 8.41M 4.39M
Current deferred revenue - - - -0.18M -0.26M
Net debt -52.94M - -65.76M -15.26M -28.17M
Short term debt 0.36M - 0.31M 0.18M 0.26M
Short long term debt total 0.62M - 1.11M 0.32M 0.94M
Other stockholder equity - - - -21.92M -30.61M
Property plant equipment - - - 1.04M 1.63M
Total current assets 482.23M 177.53M 85.61M 31.87M 39.25M
Long term investments 221.20M - - - -
Net tangible assets - - - 23.50M 34.90M
Short term investments 394.00M - - - 0.00M
Net receivables 34.13M - 18.00M 16.25M 10.07M
Accounts payable 9.89M 8.75M 7.53M 4.92M 2.57M
Accumulated other comprehensive income 9.62M - 5.81M 5.83M 8.74M
Non currrent assets other - - 4.05M -5.29M 0.02M
Non current assets total 226.28M 5.75M 5.62M 5.29M 6.10M
Capital lease obligations 0.62M 1.02M - 0.32M 0.94M
Long term debt total - - - 0.14M 0.68M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments -615.63M -0.98M -0.31M -0.48M 33.07M
Change to liabilities - - - 4.34M 0.26M
Total cashflows from investing activities -616.16M -0.98M -0.31M -0.48M 32.68M
Net borrowings - - - -0.23M -0.18M
Total cash from financing activities 563.22M 138.66M 90.19M 11.44M -0.18M
Change to operating activities - - - -0.14M 0.53M
Net income -43.34M -50.30M -37.73M -22.79M -13.86M
Change in cash -99.49M 86.18M 51.30M -13.54M 10.67M
Begin period cash flow 153.05M 66.87M 15.57M 29.11M 18.44M
End period cash flow 53.56M 153.05M 66.87M 15.57M 29.11M
Total cash from operating activities -44.52M -51.56M -38.59M -24.42M -21.78M
Issuance of capital stock 600.22M 145.82M 92.06M 12.65M -
Depreciation 1.20M - 1.07M 0.88M 0.84M
Other cashflows from investing activities - - 0.00M 0.01M 33.07M
Change to account receivables -10.20M -5.74M -2.44M -6.16M -9.83M
Sale purchase of stock -36.61M -6.80M -1.57M -0.98M -0.98M
Other cashflows from financing activities -0.40M -6.80M -0.29M -0.23M -0.18M
Change to netincome - - - -0.55M 0.18M
Capital expenditures 0.53M 0.98M 0.31M 0.49M 0.39M
Change in working capital -7.89M -2.56M -2.16M -6.16M -9.83M
Stock based compensation - - 0.25M -0.07M 0.61M
Other non cash items 5.51M -49.00M 0.23M -2.51M -8.76M
Free cash flow -45.05M -52.54M -38.90M -24.91M -22.17M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PYC
PYC Therapeutics Ltd		 -0.05
2.59%		 1.88 - 12.00 73.11 2.63 25.02 -8.41
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

PYC Therapeutics Ltd

PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Harry Perkins Institute of Medical Research, Nedlands, WA, Australia, 6009

61 8 6151 0992

https://pyctx.com

Name Title Year Born
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) CEO & Exec. Director 1983
Mr. Andrew Taylor B.Com., C.A. Chief Financial Officer NA
Prof. Sue Fletcher Chief Scientific Officer NA
Dr. May Orfali M.B.A., M.D. Chief Medical Officer of US Operations 1968
Dr. Glenn Noronha Chief Devel. Officer 1965
Mr. Kevin Ronald Hart B.Com, B.Comm (Hons), C.A., F.C.A., FCA Company Sec. 1962
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) CEO & Executive Director 1983
Mr. Andrew Taylor B.Com., C.A. CFO & Company Secretary NA
Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A. Company Secretary 1962
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) CEO & Executive Director 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…